The Peptide Reclassification Everyone's Talking About: A Pharmacist's Take on What RFK Jr's Announcement Actually Means
Writing for Pharmacy Times, a pharmacist walks through why HHS Secretary Robert F. Kennedy Jr.'s February 2026 announcement — that roughly 14 of 19 restricted peptides would move back to a more permissive compounding category — has been widely misunderstood, arguing the public conversation repeatedly conflates three very different tiers of compound: fully FDA-approved peptide drugs, legally compoundable but not FDA-approved peptides, and unregulated gray-market "research peptides" that remain a separate matter entirely.
This is a summary. The reporting is Pharmacy Times's, and the link below goes to the original article.